Skip to main content

Table 5 Combined effects of metabolic syndrome and VEGF 3′-UTR variants on colon cancer and rectal cancer risks

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

 

CC risk

RC risk

 

Without MetS

With MetS

Without MetS

With MetS

Genotype

AOR (95% CI)

p

AOR (95% CI)

p

AOR (95% CI)

p

AOR (95% CI)

p

VEGF 1451CC

1.00 (reference)

 

2.17 (1.43 - 3.28)

<.001

1.00 (reference)

 

2.22 (1.38 - 3.57)

0.001

VEGF 1451CT+TT

1.18 (0.79 - 1.77)

0.416

1.76 (0.98 - 3.16)

0.060

1.67 (1.07 - 2.61)

0.023

3.15 (1.74 - 5.70)

<.001

VEGF 1612GG

1.00 (reference)

 

1.68 (1.12 - 2.53)

0.013

1.00 (reference)

 

1.94 (1.24 - 3.01)

0.003

VEGF 1612GA+AA

0.71 (0.46 - 1.09)

0.117

1.81 (1.03 - 3.19)

0.040

0.69 (0.42 - 1.14)

0.148

1.66 (0.88 - 3.15)

0.117

VEGF 1725GG

1.00 (reference)

 

1.88 (1.29 - 2.73)

0.001

1.00 (reference)

 

2.17 (1.44 - 3.27)

<.001

VEGF 1725GA+AA

1.34 (0.72 - 2.49)

0.360

2.68 (1.30 - 5.55)

0.008

1.82 (0.95 - 3.48)

0.072

2.49 (1.11 - 5.57)

0.027

  1. Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and p values were adjusted by age and gender.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us